Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Aurinia Pharmaceuticals

NASDAQ AUPH
$5.77 0.46 7.97%
Today share price
Canada
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

830.96M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
797.68M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.36
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
144.01M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-35.82 %

Upcoming events Aurinia Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Aurinia Pharmaceuticals

Stock analysis Aurinia Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-13.28 17.33
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
2.20 6.54
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-16.64 8.74
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.69 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-17.40 4.05

Price change Aurinia Pharmaceuticals per year

9.72$ 24.18$
Min Max

Summary analysis Aurinia Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Aurinia Pharmaceuticals

Revenue and net income Aurinia Pharmaceuticals

All parameters

Stock news Aurinia Pharmaceuticals

All news
13 November 2023 в 14:20

Aurinia Pharmaceuticals Partner Files NDA in Japan for Voclosporin

13 November 2023 в 14:20

Aurinia Pharmaceuticals Partner Files NDA in Japan for Voclosporin

29 June 2023 в 23:30

Aurinia Pharmaceuticals to Look at Strategic Alternatives as Two Board Members Resign

29 June 2023 в 23:25

Aurinia Pharmaceuticals to Look at Strategic Alternatives as Two Board Members Resign

6 January 2023 в 20:01

Aurinia Pharmaceuticals Shares Up 10% on Estimated 4Q Revenue Gain

6 January 2023 в 20:00

Aurinia Pharmaceuticals Shares Up 10% on Estimated 4Q Revenue Gain

6 January 2023 в 14:35

Aurinia Pharmaceuticals Sees Higher 4Q Rev

6 January 2023 в 14:30

Aurinia Pharmaceuticals Sees Higher 4Q Rev

19 September 2022 в 18:41

Aurinia Pharmaceuticals: EC Approved Lupkynis for Active Lupus Nephritis >AUPH

19 September 2022 в 18:35

Aurinia Pharmaceuticals: EC Approved Lupkynis for Active Lupus Nephritis >AUPH

26 July 2022 в 21:36

Aurinia Pharmaceuticals Issues Notice on IPR Review Related to Lupkynis Patent

26 July 2022 в 21:36

Aurinia Pharmaceuticals Issues Notice on IPR Review Related to Lupkynis Patent

22 July 2022 в 13:41

Aurinia Pharmaceuticals Gets Positive CHMP Opinion for Voclosporin

22 July 2022 в 13:35

Aurinia Pharmaceuticals Gets Positive CHMP Opinion for Voclosporin

10 May 2022 в 20:25

Aurinia Pharmaceuticals Shares Advance 22% on Jump in 1Q Revenue

10 May 2022 в 20:25

Aurinia Pharmaceuticals Shares Advance 22% on Jump in 1Q Revenue

28 October 2021 в 15:20

Aurinia Pharmaceuticals downgraded to perform from outperform at Oppenheimer

25 October 2021 в 16:01

Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest >AUPH

25 October 2021 в 15:55

Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest >AUPH

23 October 2021 в 04:15

Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals

About company Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Address:
4464 Markham Street, Victoria, BC, Canada, V8Z 7X8
Company name: Aurinia Pharmaceuticals
Issuer ticker: AUPH
ISIN: CA05156V1022
Country: Canada
Exchange: NASDAQ
Currency: $
IPO date: 1999-01-26
Sector: Healthcare
Industry: Biotechnology
Site: https://www.auriniapharma.com

On which stock exchange are Aurinia Pharmaceuticals (AUPH) stocks traded?

Aurinia Pharmaceuticals (AUPH) stocks are traded on NASDAQ.

What is the ticker of Aurinia Pharmaceuticals stocks (AUPH)?

The stock ticker of Aurinia Pharmaceuticals’s stocks or in other words, the code is AUPH. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Aurinia Pharmaceuticals (AUPH) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Aurinia Pharmaceuticals (AUPH) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Aurinia Pharmaceuticals (AUPH) stocks traded?

Aurinia Pharmaceuticals (AUPH) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Aurinia Pharmaceuticals (AUPH) stocks today?

The current price of Aurinia Pharmaceuticals stocks on 17.05.2024 is 5.77 dollars. per share.

What is the dynamics of Aurinia Pharmaceuticals (AUPH) stocks from the beginning of the year?

Aurinia Pharmaceuticals (AUPH) quotes have increased by -33.98% from the beginning of the year up to 5.77 dollars. per 1 stocks.

How much did Aurinia Pharmaceuticals (AUPH) stocks increase in мае 2024?

This month Aurinia Pharmaceuticals (AUPH) quotes have increased by 10.96% to 5.77 dollars. per share.

How much are Aurinia Pharmaceuticals (AUPH) stocks worth?

Today, on October, 17.05.2024 Aurinia Pharmaceuticals’s (AUPH) stocks cost 5.77 dollars..

What is the market capitalization of Aurinia Pharmaceuticals (AUPH)?

Capitalization is the market value of Aurinia Pharmaceuticals (AUPH) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 17.05.2024, the market capitalization of Aurinia Pharmaceuticals (AUPH) is estimated at about 830955010 dollars.